IL155279A0 - Methods of treatment using wisp polypeptides - Google Patents

Methods of treatment using wisp polypeptides

Info

Publication number
IL155279A0
IL155279A0 IL15527901A IL15527901A IL155279A0 IL 155279 A0 IL155279 A0 IL 155279A0 IL 15527901 A IL15527901 A IL 15527901A IL 15527901 A IL15527901 A IL 15527901A IL 155279 A0 IL155279 A0 IL 155279A0
Authority
IL
Israel
Prior art keywords
treatment
administration
cartilage
injury
repair
Prior art date
Application number
IL15527901A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL155279A0 publication Critical patent/IL155279A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL15527901A 2000-10-16 2001-10-12 Methods of treatment using wisp polypeptides IL155279A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24122200P 2000-10-16 2000-10-16
PCT/US2001/032142 WO2002033085A2 (fr) 2000-10-16 2001-10-12 Techniques de traitement utilisant des polypeptides wisp

Publications (1)

Publication Number Publication Date
IL155279A0 true IL155279A0 (en) 2003-11-23

Family

ID=22909763

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15527901A IL155279A0 (en) 2000-10-16 2001-10-12 Methods of treatment using wisp polypeptides
IL155279A IL155279A (en) 2000-10-16 2003-04-08 Use of a wisp polypeptide for the preparation of medicaments for the treatment of mammalian cartilage cells or mammalian cartilage tissue damaged from a degenerative cartilagenous disorder or injury
IL200484A IL200484A (en) 2000-10-16 2009-08-19 Use of wisp polypeptides or biologically active fragment thereof for the preparation of medicaments for treatment of mammalian cartilage cells or tissue

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL155279A IL155279A (en) 2000-10-16 2003-04-08 Use of a wisp polypeptide for the preparation of medicaments for the treatment of mammalian cartilage cells or mammalian cartilage tissue damaged from a degenerative cartilagenous disorder or injury
IL200484A IL200484A (en) 2000-10-16 2009-08-19 Use of wisp polypeptides or biologically active fragment thereof for the preparation of medicaments for treatment of mammalian cartilage cells or tissue

Country Status (10)

Country Link
US (2) US7687460B2 (fr)
EP (3) EP1927659B1 (fr)
JP (1) JP4202128B2 (fr)
AT (3) ATE456655T1 (fr)
AU (2) AU2002224377B2 (fr)
CA (1) CA2425145C (fr)
DE (2) DE60141236D1 (fr)
ES (3) ES2338492T3 (fr)
IL (3) IL155279A0 (fr)
WO (1) WO2002033085A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155279A0 (en) * 2000-10-16 2003-11-23 Genentech Inc Methods of treatment using wisp polypeptides
WO2005025603A2 (fr) * 2003-09-11 2005-03-24 Genentech, Inc. Procedes d'utilisation d'antagonistes de wisp
SE0401069D0 (sv) * 2004-04-26 2004-04-26 Anamar Medical Ab Use of Compounds for the Treatment of Diseases and Conditions
CN101490245B (zh) * 2006-06-20 2013-01-16 建新公司 无血清培养基及其在软骨细胞扩增中的用途
WO2008134054A1 (fr) * 2007-04-26 2008-11-06 Genera Doo Biomarqueurs sanguins pour les fractures osseuses et les lésions cartilagineuses
CA2710554A1 (fr) 2008-01-18 2009-10-15 Burnham Institute For Medical Research Procedes et compositions lies a l'internalisation de peptides rgd
BRPI1015424B1 (pt) * 2009-06-22 2022-01-18 Burnham Institute For Medical Research Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição
MY160951A (en) 2009-07-14 2017-03-31 Scripps Research Inst Mesenchymal stem cell differentiation
WO2012104836A1 (fr) * 2011-01-31 2012-08-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Snx9 en tant que nouveau biomarqueur pour l'inflammation chronique et l'immunosuppression associée et nouveau régulateur de l'expression des récepteurs de cellules t et fonction
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
AU2017207445B2 (en) * 2016-01-14 2023-12-07 Spinalcyte, Llc Cellular blend for the regeneration of chondrocytes or cartilage type cells
JP2019527193A (ja) * 2016-06-02 2019-09-26 ソシエテ・デ・プロデュイ・ネスレ・エス・アー サルコペニア及び筋損傷を治療する方法
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
KR102167443B1 (ko) * 2019-03-25 2020-10-19 주식회사 카티프라임 체외 골관절염 모델 및 이를 이용한 골관절염 치료제 스크리닝 방법
CN111700881B (zh) * 2020-07-02 2021-05-18 四川大学 Wnt蛋白＼ZIF-8纳米复合体、其制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
EP0736034A4 (fr) 1993-12-22 1999-02-03 Merck & Co Inc Adn codant le facteur de croissance wnt-x
US5444047A (en) 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
WO2000053753A2 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Activation ou inhibition de l'angiogenese et de la cardiovascularisation
AU7610396A (en) 1996-11-08 1998-06-03 Human Genome Sciences, Inc. Connective tissue growth factor-3
CA2294564A1 (fr) * 1997-06-19 1998-12-23 Incyte Pharmaceuticals, Inc. Polynucleotides codant une proteine de type facteur de croissance
US20020192209A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
ES2313756T3 (es) 1997-10-29 2009-03-01 Genentech, Inc. Usos de polipeptido secretado wisp-1 inducido por wnt-1.
WO1999062927A1 (fr) * 1998-06-05 1999-12-09 Human Genome Sciences, Inc. Facteur de croissance 4 du tissu conjonctif
KR100342045B1 (ko) * 1999-04-16 2002-06-27 김순택 2차전지
AU6088900A (en) 1999-07-23 2001-02-13 Case Western Reserve University Novel methods and reagents useful in the treatment of osteoarthritis
GB9930768D0 (en) 1999-12-29 2000-02-16 Pfizer Ltd Composition
US20020063763A1 (en) * 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
IL155279A0 (en) * 2000-10-16 2003-11-23 Genentech Inc Methods of treatment using wisp polypeptides

Also Published As

Publication number Publication date
ES2304401T3 (es) 2008-10-16
ES2338492T3 (es) 2010-05-07
EP1927659A1 (fr) 2008-06-04
JP4202128B2 (ja) 2008-12-24
DE60133301D1 (de) 2008-04-30
IL200484A (en) 2012-05-31
DE60141236D1 (de) 2010-03-18
EP2180053A3 (fr) 2010-11-10
EP1326980B1 (fr) 2008-03-19
DE60133301T2 (de) 2009-05-14
ATE389719T1 (de) 2008-04-15
US20050054563A1 (en) 2005-03-10
CA2425145C (fr) 2011-08-30
AU2002224377B2 (en) 2007-07-19
WO2002033085A9 (fr) 2002-07-25
ES2381935T3 (es) 2012-06-01
AU2002224377B8 (en) 2002-04-29
AU2437702A (en) 2002-04-29
EP2180053A2 (fr) 2010-04-28
EP1927659B1 (fr) 2010-01-27
US7687460B2 (en) 2010-03-30
ATE544855T1 (de) 2012-02-15
ATE456655T1 (de) 2010-02-15
US8138152B2 (en) 2012-03-20
EP2180053B1 (fr) 2012-02-08
US20100093628A1 (en) 2010-04-15
IL200484A0 (en) 2010-04-29
EP1326980A2 (fr) 2003-07-16
WO2002033085A3 (fr) 2003-04-17
IL155279A (en) 2011-05-31
WO2002033085A2 (fr) 2002-04-25
JP2004534720A (ja) 2004-11-18
CA2425145A1 (fr) 2002-04-25

Similar Documents

Publication Publication Date Title
IL200484A0 (en) Use of wisp polypeptides wisp for the preparation of medicaments
AU4935701A (en) Use of insulin for the treatment of cartilagenous disorders
ATE338569T1 (de) Osteogene vorrichtungen und verfahren zu ihrer verwendung zur knochenreparatur
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
FR13C0062I1 (fr)
ATE258984T1 (de) Bmp-11 zusammensetzungen
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
WO2004019884A3 (fr) Agents et procedes pour stimuler la formation osseuse
PL331922A1 (en) Method of inhibiting fibrosis by means of an antagonist of somatotropin release inhibiting factor
ES2182902T3 (es) Sistema de reparacion de superficies de articulaciones.
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
DE69821793D1 (de) Neuronale verwendungen des bmp-11
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
WO2002092013A3 (fr) Methodes de traitement des maladies du foie et des lesions du foie a l'aide de l'hormone de croissance et de la proteine foxm1b
IT1293305B1 (it) Sali di acidi difosfonici e loro impiego farmacologico nel trattamento dell'osteoporosi
ES2196349T3 (es) Uso de galanina para reparar lesiones en los nervios.
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
WO1997048368A3 (fr) Naphtyridines affectant le recepteur il-4 et le facteur g-csf
BR9709007A (pt) Uso de azaspirano substituìdo no tratamento da asma.